This study reports the immunomodulatory activity on human Monocyte Derived Dendritic Cells (MDDCs) of a vaccine preparation shown to be effective against an HPV16-related tumour in an animal model. The vaccine is composed of extract from Nicotiana benthamiana leaves containing HPV16 E7 protein expressed by a potato virus X-derived vector (NbPVX-E7). The effect of the extract was evaluated on MDDC differentiation and maturation by monitoring the phenotypic expression of specific markers. The results show that NbPVX-E7 does not induce monocyte differentiation to dendritic cells, but does induce MDDC maturation. Plant extract does not influence MDDC-uptake of E7-FITC while it significantly improves the Ovalbumin-FITC uptake, considered as a model antigen. Importantly, NbPVX-E7-pulsed MDDCs/PBMCs are able to prime human blood-derived lymphocytes from healthy individuals to induce HPV16 E7-specific cytotoxic activity. This is a propaedeutic study for a possible use of E7-containing plant extract in human immunotherapy of HPV-related lesions.
CampoMS. Papillomavirus Research: From Natural History to Vaccines and Beyond. Edited by CampoMS, Caister Academic Press, Norwich, UK, 2006; p. 1–424.
2.
MüllerMGissmannL. A long way: history of the prophylactic papillomavirus vaccine. Dis Markers2007; 23:331–36.
3.
WuTC. Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer. Eur J Immunol2007; 37:310–14.
4.
HungCFMaBMonieATsenSWWuTC. Therapeutic human papillomavirus vaccines: current clinical trials and future directionsExpert Opin Biol Ther2008; 8:421–39.
5.
KanodiaSDa SilvaDMKastWM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer2008; 122: 247–59.
6.
BelloneSPecorelliSCannonMJSantinAD. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther2007; 7:1473–86.
7.
FranconiRDi BonitoPDibelloF. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumour protection. Cancer Research2002; 62:3654–58.
8.
FranconiRMassaSIllianoEMullarACirilliAAccardiLDi BonitoPGiorgiCVenutiA. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine. Int J Immunopathol Pharmacol2006; 19: 187–97.
9.
Di BonitoPGrassoFMochiS. Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. Infect Agent Cancer2006; 8:1–6.
10.
FrankenKLHiemstraHSvan MeijgaardenKESubrontoYden HartighJOttenhoffTHDrijfhoutJW. Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr Purif2000; 18:95–99.
11.
ReicheltPSchwarzCDonzeauM. Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr Purif2006; 46: 483–88.
12.
SallustoFLanzavecchiaA. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med1994; 179:1109–18.
13.
Fanales-BelasioEMorettiSNappiFBarillariGMichelettiFCafaroAEnsoliB. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol2002; 168:197–206.
14.
DenglerWASchulteJBergerDPMertelsmannRFiebigHH. Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs1995; 6:522–32.
15.
KassRAghaJBelloneS. In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. J Surg Res2003; 112: 189–97.
16.
SantinADHermonatPLRavaggiAChiriva-InternatiMZhanDPecorelliSParhamGPCannonMJ. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol1999; 73:5402–10.
17.
SantinADBelloneSPalmieriM. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol2006; 100:469–78.
18.
SteinGMBussingASchietzelM. Activation of dendritic cells by an aqueous mistletoe extract and mistletoe lectin-3 in vitro. Anticancer Res2002; 22: 267–74.
19.
SteinGMBussingASchietzelM. Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Res2002; 22:4215–19.
20.
BradleyWGWidenRHWeiserAM. The novel differentiation of human blood mononuclear cells into CD1a-negative dendritic cells is stimulated in the absence of exogenous cytokines by an extract prepared from pinecones. Int Immunopharmacol2003; 3:209–23.
D'AnnaRLe BuanecHBizziniBBurnyAGiannouliCZaguryJFGalloRCZaguryDD'AlessioP. Human papillomavirus-16-E7 oncoprotein enhances the expression of adhesion molecules in cervical endothelial cells but not in human umbilical vein endothelial cells. J Hum Virol2001; 4:85–95.
24.
RichardJPMelikovKVivesERamosCVerbeureBGaitMJChernomordikLVLebleuB. Cell-penetrating peptides. A re-evaluation of the mechanism of cellular uptake. J Biol Chem2003; 278:585–90.
25.
SäälikPElmquistAHansenMPadariKSaarKVihtKLangelUPoogaM. Protein cargo delivery properties of cell-penetrating peptides. A comparative study Bioconjug Chem2004; 15:1246–53.
26.
DuchardtFFotin-MleczekMSchwarzHFischerRBrockR. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic2007; 8:848–66.
27.
SavinaAAmigorenaS. Phagocytosis and antigen presentation in dendritic cellsImmunol Rev2007; 219:143–56.
